概括
现在转移性前列腺癌的治疗包括强化组合疗法,包括割和新型荷尔蒙药物或化疗. 管理治疗副作用和结合精密药物,如对PARP抑制剂的BRCA1 / 2测试,对于改善患者生存至关重要.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 转移性前列腺癌的治疗方法随着加强的方法而显著发展.
- 目前的标准包括结合疗法与割作为骨干,增强了新的荷尔蒙疗法和/或化疗.
研究的目的:
- 概述转移性前列腺癌的当代治疗格局.
- 突出管理与治疗相关的副作用的重要性以及精准医学的出现.
主要方法:
- 对最近转移性前列腺癌管理方面的进展进行了回顾.
- 整合关于组合疗法,放射治疗和精准医学策略的数据.
主要成果:
- 结合治疗与割和新药是新的标准.
- 建议对主要瘤进行放射治疗,以最小化转移性传播.
- 由于增加了生存率,心血管和骨健康管理至关重要.
- 为了获得PARP抑制剂的资格,BRCA1/2突变测试是强制性的.
结论:
- 现代转移性前列腺癌治疗强调组合疗法和精准医学.
- 长期生存需要积极管理治疗副作用.
- 基于基因突变 (例如BRCA1/2) 的向疗法代表了前列腺癌精确瘤学的关键方面.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


